Juno Therapeutics (JUNO) IPO Opens Up 63%
Get Alerts JUNO Hot Sheet
Join SI Premium – FREE
Today's IPO for Juno Therapeutics (NASDAQ: JUNO) opened for trading at $39 after pricing 11,022,917 shares of common stock at a price to the public of $24 per share, above the expected $21-$23 range which was recently raised from $15-$18. The number of shares offered was raised from 9,250,000 shares.
Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock to cover over-allotments, if any.
Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, and Goldman, Sachs & Co. are acting as lead book-running managers for the offering. Leerink Partners LLC is acting as a co-manager.
Juno Therapeutics, Inc. is a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- AGBA Group Holding (AGBA) selling off into close, down over 17%
- Tesla (TSLA) soars on Q1 print
Create E-mail Alert Related Categories
Hot IPOs, IPOs, Momentum Movers, Trader TalkRelated Entities
JPMorgan, Morgan Stanley, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!